As anêmonas do mar utilizam rico complexo proteico para capturar suas presas e se defender de predadores. A peçonha destes animais contem neurotoxinas (35 kDa), com ação em canais iônicos específicos, e hemolisinas (1820 kDa), que atuam formando poros em membranas. No entanto, pouco se conhece sobre a atividade biológica de substâncias de baixo peso molecular isoladas da peçonha destes animais. Foi demonstrado, pelo nosso grupo, que a Bunodosina 391 (BDS 391), um composto de baixo peso molecular isolado da peçonha da anêmona do mar Bunodosoma cangicum, induz potente efeito antinociceptivo periférico, em modelos experimentais de dor aguda e persistente. Ensaios farmacológicos mostraram que a atividade analgésica do BDS 391 é mediada pela ativação de receptores serotoninérgicos 5-HT3. O BDS 391 é um composto bromado formado por um núcleo molecular semelhante a serotonina (5-HT), conectado, por meio de uma ligação peptídica, a uma histidina. A semelhança estrutural com a 5-HT e o envolvimento de receptores 5-HT3 no efeito antinociceptivo deste composto, torna de especial interesse a ampliação da caracterização dos mecanismos moleculares envolvidos na ação do BDS 391. Há evidências crescentes da co-expressão de receptores 5-HT e TRPV1 e a interação entre esses dois receptores na modulação da excitabilidade de neurônios sensitivos envolvidos na nocicepção. O receptor TRPV1 é considerado um receptor polimodal, uma vez que pode ser ativado por diversos estímulos. Baseado em estudos farmacológicos, mostrando que o BDS 391 apresenta potente efeito antinociceptivo em modelo de hipernocicepção mecânica, mediado pela ativação de receptores 5-HT3 periféricos o presente projeto de pesquisa teve como objtivo ampliar a caracterização dos mecanismos moleculares envolvidos na ação do BDS 391 investigando a interação deste composto com os receptores 5-HT3, por meio de ensaios de ligação (binding). Uma vez que nossos resultados demonstraram que o composto BDS 391 não é capaz de interagir diretamente com os receptores 5-HT3, sugerindo que o envolvimento destes receptores no efeito analgésico induzido pelo BDS 391 pode decorrer de uma acão indireta do BDS 391, avaliamos outros possíveis alvos farmacológicos para este composto. Por tanto investigamos, por meiode ensaios eletrofisiológicos e ensaios de imageamento de influxo de Ca2+ em cultura de neurônios do DRG de ratos, a possível ação do BDS 391 sobre correntes iônicas Ca2+ em canais para cálcio dependentes de voltagens (Cavs). Outro alvo avaliado foram os canais TRPV1. Foram realizados emsaios in vivo, utilizando modelo de hiperalgesia térmica induzida pela capsaicina, e ensaios in vitro (imageamento do influxo de Ca2+). Nossos resultados evidenciaram que o BDS 391 não interage com os Cavs, porem bloqueia o influxo de Ca2+ induzido pela capsaicina, além de inibira hiperalgesia térmica induzida pela capsaicina. Em conjunto, estes dados sugerem que os canais TRPV1 são alvos importantes da ação do BDS 391. / Sea anemones employ a wide range of bioactive compounds to capture their prey or fend off possible predators. Sea anemone venom contains neurotoxins (3-5 kDa), with action on ion channels, and also hemolysin (18-20 kDa), which acts by forming pores in membranes. However, little is known about the biological activity of low molecular weight substances isolated from the venom of these animals. One of these substances is Bunodosine 391 (BDS 391), a low molecular weight (391 Da) and non-peptidic compound purified from the venom of the Brazilian Bunodosoma cangicum sea anemone. We have demonstrated that BDS 391, administered by intraplantar (i.pl.) route into a rat hind paw, induces potent peripheral antinociceptive effect in models of acute and chronic pain. Pharmacological studies have shown that the antinociceptive effect of the BDS 391 is mediated by activation of 5-HT3 receptors. Studies on the structure of BDS 391 have demonstrated that this compound is made up of a bromoindole group connected to histidine. Data from the literature have shown that the peripheral release of 5-HT interferes with thermal hyperalgesia, via modulation of TRPV1 receptors. The aim of the present work is to further characterize the mechanisms involved in the antinociceptive effect of BDS 391 (a) evaluating the ability of this substance to directly activate 5-HT3 receptors, (b) characterizing the effect of BDS 391 on capsaicin-evoked thermal hyperalgesia and (c) investigating the involvement of TRPV1 ion channels in this effect. Pharmacological studies have shown that BDS 391 induces antinociception in the capsaicin-evoked thermal hyperalgesia. Ondansentron (5-HT3 receptor antagonist) inhibits the effect of BDS 391, indicating the involvement of 5-HT3 in the antinociceptive effect of this substance. However, binding studies have shown that BDS 391 does not directly interact with the 5-HT3 receptor. The possible effect of BDS 391 on TRPV1 ion channels was investigated in vitro, through Ca2+ imaging studies. Cultured DRG neurons were used for Ca2+ imaging. BDS 391 inhibited capsaicin-evoked Ca2+ influx in DRG neurons, indicating a modulatory action on the activity of TRPV1. Our results suggest that the antinociceptive effect of BDS 391 could involve the inhibition of TRPV1 channels and, indirectly, the modulation of 5-HT3 receptors.

As anêmonas do mar utilizam rico complexo proteico para capturar suas presas e se defender de predadores. A peçonha destes animais contem neurotoxinas (35 kDa), com ação em canais iônicos específicos, e hemolisinas (1820 kDa), que atuam formando poros em membranas. No entanto, pouco se conhece sobre a atividade biológica de substâncias de baixo peso molecular isoladas da peçonha destes animais. Foi demonstrado, pelo nosso grupo, que a Bunodosina 391 (BDS 391), um composto de baixo peso molecular isolado da peçonha da anêmona do mar Bunodosoma cangicum, induz potente efeito antinociceptivo periférico, em modelos experimentais de dor aguda e persistente. Ensaios farmacológicos mostraram que a atividade analgésica do BDS 391 é mediada pela ativação de receptores serotoninérgicos 5-HT3. O BDS 391 é um composto bromado formado por um núcleo molecular semelhante a serotonina (5-HT), conectado, por meio de uma ligação peptídica, a uma histidina. A semelhança estrutural com a 5-HT e o envolvimento de receptores 5-HT3 no efeito antinociceptivo deste composto, torna de especial interesse a ampliação da caracterização dos mecanismos moleculares envolvidos na ação do BDS 391. Há evidências crescentes da co-expressão de receptores 5-HT e TRPV1 e a interação entre esses dois receptores na modulação da excitabilidade de neurônios sensitivos envolvidos na nocicepção. O receptor TRPV1 é considerado um receptor polimodal, uma vez que pode ser ativado por diversos estímulos. Baseado em estudos farmacológicos, mostrando que o BDS 391 apresenta potente efeito antinociceptivo em modelo de hipernocicepção mecânica, mediado pela ativação de receptores 5-HT3 periféricos o presente projeto de pesquisa teve como objtivo ampliar a caracterização dos mecanismos moleculares envolvidos na ação do BDS 391 investigando a interação deste composto com os receptores 5-HT3, por meio de ensaios de ligação (binding). Uma vez que nossos resultados demonstraram que o composto BDS 391 não é capaz de interagir diretamente com os receptores 5-HT3, sugerindo que o envolvimento destes receptores no efeito analgésico induzido pelo BDS 391 pode decorrer de uma acão indireta do BDS 391, avaliamos outros possíveis alvos farmacológicos para este composto. Por tanto investigamos, por meiode ensaios eletrofisiológicos e ensaios de imageamento de influxo de Ca2+ em cultura de neurônios do DRG de ratos, a possível ação do BDS 391 sobre correntes iônicas Ca2+ em canais para cálcio dependentes de voltagens (Cavs). Outro alvo avaliado foram os canais TRPV1. Foram realizados emsaios in vivo, utilizando modelo de hiperalgesia térmica induzida pela capsaicina, e ensaios in vitro (imageamento do influxo de Ca2+). Nossos resultados evidenciaram que o BDS 391 não interage com os Cavs, porem bloqueia o influxo de Ca2+ induzido pela capsaicina, além de inibira hiperalgesia térmica induzida pela capsaicina. Em conjunto, estes dados sugerem que os canais TRPV1 são alvos importantes da ação do BDS 391. / Sea anemones employ a wide range of bioactive compounds to capture their prey or fend off possible predators. Sea anemone venom contains neurotoxins (3-5 kDa), with action on ion channels, and also hemolysin (18-20 kDa), which acts by forming pores in membranes. However, little is known about the biological activity of low molecular weight substances isolated from the venom of these animals. One of these substances is Bunodosine 391 (BDS 391), a low molecular weight (391 Da) and non-peptidic compound purified from the venom of the Brazilian Bunodosoma cangicum sea anemone. We have demonstrated that BDS 391, administered by intraplantar (i.pl.) route into a rat hind paw, induces potent peripheral antinociceptive effect in models of acute and chronic pain. Pharmacological studies have shown that the antinociceptive effect of the BDS 391 is mediated by activation of 5-HT3 receptors. Studies on the structure of BDS 391 have demonstrated that this compound is made up of a bromoindole group connected to histidine. Data from the literature have shown that the peripheral release of 5-HT interferes with thermal hyperalgesia, via modulation of TRPV1 receptors. The aim of the present work is to further characterize the mechanisms involved in the antinociceptive effect of BDS 391 (a) evaluating the ability of this substance to directly activate 5-HT3 receptors, (b) characterizing the effect of BDS 391 on capsaicin-evoked thermal hyperalgesia and (c) investigating the involvement of TRPV1 ion channels in this effect. Pharmacological studies have shown that BDS 391 induces antinociception in the capsaicin-evoked thermal hyperalgesia. Ondansentron (5-HT3 receptor antagonist) inhibits the effect of BDS 391, indicating the involvement of 5-HT3 in the antinociceptive effect of this substance. However, binding studies have shown that BDS 391 does not directly interact with the 5-HT3 receptor. The possible effect of BDS 391 on TRPV1 ion channels was investigated in vitro, through Ca2+ imaging studies. Cultured DRG neurons were used for Ca2+ imaging. BDS 391 inhibited capsaicin-evoked Ca2+ influx in DRG neurons, indicating a modulatory action on the activity of TRPV1. Our results suggest that the antinociceptive effect of BDS 391 could involve the inhibition of TRPV1 channels and, indirectly, the modulation of 5-HT3 receptors.

Made available in DSpace on 2016-06-02T19:22:50Z (GMT). No. of bitstreams: 1 2381.pdf: 1192808 bytes, checksum: b6bdb4da58bced09244d3a1f38c4a657 (MD5) Previous issue date: 2009-04-24 / Universidade Federal de Sao Carlos / The exposure of animals to aversive situations, such as elevated plus-maze (EPM), activates serotonergic pathways with projections into structures involved in the defense system, such as the amygdala, septum, hypothalamus, hippocampus and periaqueductal grey matter (PAG), producing behavioral changes that can be characterized as anxiety. However the serotonin (5-HT) presents a dual role in this modulation. Thus, while the stimulation of the receptor subtype 5-HT1A and 5-HT2 prosencephalic in structures such as amygdala and hippocampus result in potentiation of responses of anxiety in rodents, the activation of these receptors in the PAG, often tends to reduce behaviors related to anxiety . This study focused the role of 5-HT3 receptors in the PAG in the anxiety in the mice EPM test. In experiments 1 and 2, mice received infusions intra-PAG of ondansetron (0, 0.3, 1.0, 3.0 nmol/0.1 μL) and mCPBG (0, 40, 80 and 160 nmol/0.1 μL), 5-HT3 receptors antagonist and agonist, respectively. As the mCPBG not changed any of the conventional indices (% open-arm entries and % open-arm time) and risk assessment, we investigated in experiment 3 the possibility of interaction between 5-HT3 and 5-HT2 receptors. For this, we perform combined microinfusions of intra-PAG ondansetron and mCPP, an agonist of 5-HT2B/2C receptors, on behavior of maze-naïve mice. The results showed that intra-PAG infusions of ondansetron (3.0 nmol) increased the behavioral indices of anxiety. None of the doses of intra-PAG infusions of mCPBG modified the conventional and ethological indices of anxiety. The anxiolytic-like effect produced by intra-PAG infusions of mCPP (0.03 nmol) was blocked by infusions of ondansetron (1.0 nmol) in the same mesencephalic structure. All effects were observed in the absence of significant changes in locomotor activity (closed-arm entries). Our results indicate that there is a possible interaction between 5-HT3 and 5-HT2B/2C receptors modulation into the PAG of anxiety in mice. / A exposição de animais a situações aversivas, tais como o labirinto em cruz elevado (LCE), ativa vias serotoninérgicas com projeções para estruturas envolvidas no sistema de defesa tais como, amídala, septo, hipotálamo, hipocampo e substância cinzenta periaquedutal (SCP), produzindo alterações comportamentais que podem ser caracterizadas como ansiedade. Entretanto, a serotonina (5-HT) apresenta um papel dual nesta modulação. Assim, enquanto a estimulação de receptores do subtipo 5-HT1A ou 5-HT2 em estruturas prosencefálicas como, amídala e hipocampo resultam na potencialização de respostas de ansiedade em roedores, a ativação dos mesmos receptores na SCP, freqüentemente tende a diminuir comportamentos relacionados à ansiedade. Este estudo investigou o papel dos receptores 5-HT3 da SCP na modulação da ansiedade em camundongos avaliados no LCE. Nos Experimentos 1 e 2, camundongos receberam microinjeções intra-SCP de ondansetron (0, 0,3, 1,0, 3,0 nmol/0,1 μl) e mCPBG (0, 40, 80 e 160 nmol/0,1 μl), antagonista e agonista dos receptores 5-HT3, respectivamente. Como o mCPBG não alterou nenhum dos índices convencionais de ansiedade (porcentagem de entrada e tempo gasto nos braços abertos) e de avaliação de risco, verificamos no experimento 3 a possibilidade de interação entre receptores 5-HT3 e 5-HT2. Para isso, realizamos microinjeções combinadas de ondansetron e mCPP, um agonista dos receptores 5-HT2B/2C. Os resultados mostraram que microinjeções de ondansetron (3,0 nmol) aumentaram os índices convencionais de ansiedade. Nenhuma das doses de mCPBG intra-SCP, alteraram os índices convencionais e etológicos de ansiedade. O efeito ansiolítico produzido pela administração intra-SCP do mCPP (0,03 nmol), foi bloqueado pela infusão de ondansetron (1,0 nmol) na mesma estrutura mesencefálica. Todos os efeitos foram observaA exposição de animais a situações aversivas, tais como o labirinto em cruz elevado (LCE), ativa vias serotoninérgicas com projeções para estruturas envolvidas no sistema de defesa tais como, amídala, septo, hipotálamo, hipocampo e substância cinzenta periaquedutal (SCP), produzindo alterações comportamentais que podem ser caracterizadas como ansiedade. Entretanto, a serotonina (5-HT) apresenta um papel dual nesta modulação. Assim, enquanto a estimulação de receptores do subtipo 5-HT1A ou 5-HT2 em estruturas prosencefálicas como, amídala e hipocampo resultam na potencialização de respostas de ansiedade em roedores, a ativação dos mesmos receptores na SCP, freqüentemente tende a diminuir comportamentos relacionados à ansiedade. Este estudo investigou o papel dos receptores 5-HT3 da SCP na modulação da ansiedade em camundongos avaliados no LCE. Nos Experimentos 1 e 2, camundongos receberam microinjeções intra-SCP de ondansetron (0, 0,3, 1,0, 3,0 nmol/0,1 μl) e mCPBG (0, 40, 80 e 160 nmol/0,1 μl), antagonista e agonista dos receptores 5-HT3, respectivamente. Como o mCPBG não alterou nenhum dos índices convencionais de ansiedade (porcentagem de entrada e tempo gasto nos braços abertos) e de avaliação de risco, verificamos no experimento 3 a possibilidade de interação entre receptores 5-HT3 e 5-HT2. Para isso, realizamos microinjeções combinadas de ondansetron e mCPP, um agonista dos receptores 5-HT2B/2C. Os resultados mostraram que microinjeções de ondansetron (3,0 nmol) aumentaram os índices convencionais de ansiedade. Nenhuma das doses de mCPBG intra-SCP, alteraram os índices convencionais e etológicos de ansiedade. O efeito ansiolítico produzido pela administração intra-SCP do mCPP (0,03 nmol), foi bloqueado pela infusão de ondansetron (1,0 nmol) na mesma estrutura mesencefálica. Todos os efeitos foram observados sem alteração da atividade locomotora (entrada nos braços fechados). Os nossos resultados sugerem uma possível interação entre receptores 5-HT3 e 5-HT2B/2C da SCP na modulação da ansiedade em camundongos.dos sem alteração da atividade locomotora (entrada nos braços fechados). Os nossos resultados sugerem uma possível interação entre receptores 5-HT3 e 5-HT2B/2C da SCP na modulação da ansiedade em camundongos.

Les antidépresseurs ISRS (inhibiteurs sélectifs de la recapture de sérotonine) sont parmi les plus prescrits pour traiter les épisodes dépressifs majeurs. Cependant, leur efficacité n’est pas optimale. En effet, ils montrent un long délai d’action, de nombreux effets indésirables et sont inefficaces pour une proportion non négligeable de patients. La dépression étant actuellement un enjeu de santé publique majeur, il est donc nécessaire de développer de nouvelles molécules possédant un meilleur profil thérapeutique. Récemment, un intérêt croissant a été porté sur le récepteur 5-HT3, notamment depuis le développement de la vortioxétine, ISRS de nouvelle génération ayant des propriétés antagonistes pour ce récepteur localisé dans les zones cérébrales contrôlant l’humeur. Le but de ce travail de thèse a été d’étudier le rôle du récepteur 5-HT3 dans la réponse aux antidépresseurs, ainsi que dans la physiopathologie de la dépression. Dans ce cadre, nous avons utilisé une approche génétique, en caractérisant un modèle de souris knockout (KO) dont le gène de la sous-unité 3A du récepteur 5-HT3 a été invalidé. Le phénotype de ces animaux et leurs contrôles de type sauvage (Wild-Type, WT) a tout d’abord été évalué dans des tests comportementaux de screening de molécules anxiolytiques et antidépressives, puis leur réponse à des traitements aigus d’ISRS a été mesurée par ces mêmes approches. L’effet de traitements antidépresseurs chroniques a quant à lui été évalué par une technique d’électrophysiologie in vitro. Enfin, les souris ont été soumises au modèle du stress de défaite sociale chronique (CSDS), afin de déterminer le rôle du récepteur 5-HT3 dans la réponse au stress. En conditions basales, le turn-over de la sérotonine est diminué chez les souris 5-HT3 KO par rapport aux souris WT. Cet effet est accompagné par une augmentation de l’expression génique des récepteurs 5-HT1A et de leur couplage aux protéines G au niveau du noyau raphé dorsal (NRD) des souris KO par rapport aux WT. Au niveau comportemental, les souris KO 5-HT3 montrent un phénotype apparenté à celui induit par un anxiolytique et par un antidépresseur. Lorsqu’elles reçoivent une injection de citalopram, un ISRS sélectif, les souris 5-HT3 KO ne se comportent pas différemment de leurs contrôles WT dans les tests de screening des antidépresseurs. Cependant, dans ces mêmes tests, l’effet de la fluoxétine, ISRS possédant des propriétés antagonistes pour le récepteur 5-HT3, est perdu chez les souris 5-HT3 KO. Le traitement chronique par le citalopram (20 mg/kg/j) induit une désensibilisation similaire des autorécepteurs 5-HT1A localisés sur les neurones sérotoninergiques du NRD chez les animaux WT et KO. Dans les mêmes conditions, mais en utilisant une dose de citalopram plus faible (5 mg/kg/j), la désensibilisation des autorécepteurs 5-HT1A est plus forte chez les animaux KO que chez les WT, confortant ainsi l’effet potentialisateur de l’invalidation des récepteurs 5-HT3 dans l’efficacité thérapeutique des ISRS. Afin de disséquer le rôle des récepteurs 5-HT3 dans la réponse au stress chronique, le CSDS a fait l’objet d’une validation avec l’agomélatine, antidépresseur de nouvelle génération. Ce stress a engendré des altérations de la mémoire à long terme, en lien avec des modifications de l’expression génique de l’exon IV du BDNF et d’enzymes de régulation épigénétique. Ces effets délétères du stress ont été traités efficacement par l’agomélatine (50 mg/kg/j) en injection chronique, mais cette molécule n’a cependant pas modifié les effets du CSDS sur les phénotypes de type anxieux et dépressifs observés après le stress. Nous avons montré que le CSDS augmentait l’expression génique de la sous-unité 3A du récepteur 5-HT3 dans différentes structures cérébrales des souris WT. De plus, les altérations de l’expression génique de CamkIIa et SOD1 induites par le stress dans le cortex préfrontal des souris WT n’ont pas été retrouvées chez les souris 5-HT3 KO (...) / SSRI (selective serotonin reuptake inhibitor) antidepressants are among the most prescribed drugs to treat major depression. However, their efficacy is not optimal yet. Indeed, they possess a long delay of action, various side effects and show not efficacy in some patients. As depression is currently a global burden, there is a great need for new molecules with a better therapeutic efficacy. Recently, an increased attention has been taking to 5-HT3 receptors, notably since the development of vortioxetine, a new generation SSRI that antagonizes this receptor. The aim of the study was to assess the role of 5-HT3 receptor in the antidepressant response and the physiopathology of depression. In this context, we used a genetic approach, by characterizing a knockout (KO) mice model lacking the 3A subunit of the 5-HT3 receptor. Their phenotype and the one of wild-type (WT) control mice was first evaluated in behavioral tests widely used for antidepressant and anxiolytic drugs screening, then following acute SSRI treatments. Effect of chronic SSRI administration was assessed by in vitro electrophysiology. Finally, mice were submitted to the chronic social defeat stress (CSDS) model, to determine the role of 5-HT3 receptor in stress response. In basal conditions, 5-HT turnover was decreased in 5-HT3 KO mice compared with WT mice. This effect was accompanied by an increase in the 5-HT1A receptor gene expression and their coupling to G proteins at the dorsal raphe nucleus (DRN) level. 5-HT3 KO mice displayed anxiolytic-like and antidepressive-like phenotype. When injected with citalopram, a very selective SSRI, 5-HT3 KO mice behaved similarly as WT mice in antidepressant screening tests. However, in the same tests, the effect of fluoxetine, a SSRI that possesses 5-HT3 receptor antagonist properties, was blunted in 5-HT3 KO mice. Chronic treatment with citalopram (20 mg/kg/d) induced in WT and KO mice a similar desensitization of 5-HT1A autoreceptors located on DRN 5-HT neurons. In the same conditions, but using a lower citalopram dose (5 mg/kg/d), 5-HT1A autoreceptor desensitization was higher in 5-HT3 KO mice than in WT mice, thus reinforcing the potentiating effect of the 5-HT3 receptor in the SSRI efficacy. In order to assess the role of 5-HT3 receptor in chronic stress response, CSDS paradigm was validated using agomelatine, a new generation antidepressant drug. This stress model provoked long term memory alterations, linked with modifications in hippocampal mRNA levels of BDNF exon IV and epigenetic modifying enzymes. These deleterious stress effects were prevented by chronic agomelatine treatment (50 mg/kg/d), but this molecule did not modify the stress-induced anxious- and depressive-like phenotypes. We showed that subunit 3A gene expression was increased in various WT mice brain structures subjected to CSDS. Moreover, stress-induced modifications of CamkIIa and SOD1 gene expression in the prefrontal cortex of WT mice were not present in KO mice. Genetic invalidation of 5-HT3 receptor blocked the effects of social stress in some behavioral tests (splash test, saccharine preference test) and on body weight gain. Taken altogether, these data show that 5-HT3 receptor plays an important role in anxiety- and depression-related behaviors. Moreover, invalidation of this receptor increased the effect of a low dose chronic SSRI treatment, and blunted the effect of a SSRI targeting 5-HT3 receptor. These results highlight the interest of this receptor in the development of innovating therapies to treat anxio-depressive disorders. Finally, the reduced sensitivity of 5-HT3 KO mice to chronic stress suggests an involvement of this receptor in stress-related behaviors and depression physiopathology.

Les traitements actuels de la dépression présentent une efficacité partielle et nécessitent une administration pendant plusieurs semaines avant d’obtenir un effet thérapeutique. Il est donc urgent de trouver de nouvelles stratégies antidépressives. La vortioxetine (Lu AA21004) est un nouvel antidépresseur en cours de développement. À la différence des inhibiteurs sélectifs de recapture de la sérotonine (ISRS), il est multi-cibles. Il bloque non seulement le transporteur de la sérotonine (SERT) mais aussi les récepteurs 5-HT3. Afin de caractériser les effets de ce composé et d’évaluer l'implication du blocage des récepteurs 5-HT3 dans son mécanisme d’action, plusieurs marqueurs précliniques de la réponse antidépressive ont été évalués. Nous avons utilisé des approches électrophysiologiques, immunohistochimiques, comportementales et de microdialyse chez le rat. La vortioxetine augmente la prolifération cellulaire hippocampique et induit une désensibilisation des autorécepteurs 5-HT1A dès 3 jours contre 2 à 3 semaines pour les antidépresseurs classiques. Elle induit également une importante libération de sérotonine malgré une occupation partielle du SERT. Ces effets sont liés, au moins en partie, au blocage des récepteurs 5-HT3. Nous avons ensuite montré qu’un antagoniste des récepteurs 5-HT3, l’ondansetron, à très faible dose, potentialisait l’effet d’un ISRS, la paroxetine. L’ensemble de nos données in vivo et ex vivo prouvent que le blocage des récepteurs 5-HT3 participe à l’efficacité pseudo-antidépressive de la vortioxetine. Les récepteurs 5-HT3 sont donc une cible intéressante pour améliorer l’efficacité des antidépresseurs et raccourcir leur délai d’action / Therapeutic effects of current antidepressant drugs only appear after several weeks of treatment and a significant number of patients do not respond to any treatment. Thus, more effective treatments for major depression are still needed. Vortioxetine (Lu AA21004), a novel antidepressant in development, displays effective properties in human. To the difference of selective serotonin reuptake inhibitors (SSRIs), it is a multimodal serotoninergic agent. Not only does it block the 5-HT transporter but it is also a potent 5-HT3 receptor antagonist. This current study was undertaken to characterize the effects of this compound and the role of 5-HT3 blockade. Using electrophysiological, immunohistochemical, autoradiography and behavioral approaches in rats, several pre-clinical markers of antidepressant-like response were assessed. Vortioxetine increased hippocampal cell proliferation and desensitized 5-HT1A autoreceptors from 1-3 days versus 2-3 weeks for classical antidepressants. In contrast to SSRIs, it also increased 5-HT hippocampal release with an incomplete SERT occupancy. Later effects are at least partly due to 5-HT3 receptors blockade. In parallel, we also showed that the 5-HT3 receptor antagonist ondansetron potentiated the effect of the SSRI paroxetine. Taken together, our in and ex vivo findings highlight the crucial role of 5-HT3 receptor blockade in the antidepressant-like efficacy of vortioxetine. Thus, we propose that the 5-HT3 receptors are an interesting target to improve antidepressant efficacy and reduce the therapeutic delay

No description available.

Cytostatikabehandlingars emetiska biverkningar har en stor negativ inverkan på patientens livskvalitet. För behandling av cytostatikainducerat illamående och kräkningar så ges flera olika läkemedel, däribland 5-HT3-receptorblockare och NK1-receptorblockare. Syftet: finns det en skillnad i effekt, och i så fall vilken, mellan kombinationsbehandlingen NEPA (netupitant (NETU) och palonosetron (PALO)) och behandlingen APR (aprepitant) + 5-HT3-receptorblockare? Hur stor andel lindras av att få en NK1-receptorblockare (APR, NETU) utöver en 5-HT3-receptorblockare vid cytostatikabehandling? Litteraturstudie valdes som metod och 5 studier ingick med nästan 3000 deltagare. Resultaten av studierna visade på ett numeriskt övertag för NEPA över APR samt en signifikant skillnad i effekt vid tillägg av NK1-receptorblockare till behandling med 5-HT3-receptorblockare. Diskussionen ställde syftet mot resultatet genom att göra jämförande sammanfattningar av samtliga studier och diskutera och förklara fynden. Slutsatsen som drogs utifrån arbetet var att NEPA och APR behandlingen saknar signifikant skillnad, för patienten kan NEPA vara en enklare behandling att följa. Andelen som lindras av att få mot att inte få en NK1-receptorblockare var mellan 8% och 15%. / The emetic side effects that comes with chemotherapy have a big negative impact on the patient’s quality of life and is because of that important to treat to improve compliance with the chemotherapy treatment. Important antiemetic treatments include 5-hydroxitryptamin-3 (5-HT3) receptor antagonists and neurokinin-1 (NK1) receptor antagonists, they each block receptors that are involved in the emetic response that is triggered by chemotherapy treatment. The purpose of this thesis was to see if there was a difference in effect between NEPA, a fixed combination of netupitant and palonosetron, and APR combined with a 5-HT3 receptor antagonist, and if so, what the difference was. The second purpose was to find out the percent of patients that was helped by being given a NK1 receptor antagonist on top of a 5-HT3 receptor antagonist treatment. This literature study included five clinical trial studies found on the database PubMed. The results showed a numeric advantage for NEPA over APR as well as a significant difference in effect when NK1 receptor antagonists were added to 5-HT3 receptor antagonist treatment. The discussion put the purpose against the result by making comparative summaries of the studies while discussing and explaining the findings. The conclusion was that no significant difference existed between NEPA and APR-treatment, but for the patient NEPA might be an easier treatment to follow since NEPA is a single dose treatment taken on day one while APR is a treatment that is taken over three days. The usage of NK1 receptor antagonists on top of 5-HT3 receptor antagonist treatment significantly improved the relieving effects with 11%-13,1% in the overall phase for the patients.

Submitted by Automa??o e Estat?stica (sst@bczm.ufrn.br) on 2017-02-13T20:11:13Z No. of bitstreams: 1 BarbaraThaiseDaSilvaFreire_DISSERT.pdf: 2117227 bytes, checksum: ea3ed2322a685c0dbab26e3132b6aeee (MD5) / Approved for entry into archive by Arlan Eloi Leite Silva (eloihistoriador@yahoo.com.br) on 2017-02-15T23:55:52Z (GMT) No. of bitstreams: 1 BarbaraThaiseDaSilvaFreire_DISSERT.pdf: 2117227 bytes, checksum: ea3ed2322a685c0dbab26e3132b6aeee (MD5) / Made available in DSpace on 2017-02-15T23:55:52Z (GMT). No. of bitstreams: 1 BarbaraThaiseDaSilvaFreire_DISSERT.pdf: 2117227 bytes, checksum: ea3ed2322a685c0dbab26e3132b6aeee (MD5) Previous issue date: 2016-07-29 / Coordena??o de Aperfei?oamento de Pessoal de N?vel Superior (CAPES) / O envolvimento de receptores do tipo 5-HT3, assim como a rela??o do N?cleo Dorsal da Rafe na modula??o da ansiedade vem sendo citados na literatura. Levando em considera??o a grande parcela da popula??o que ? afetada pelos transtornos de ansiedade, torna-se imprescind?vel a procura por novas formas de tratamento mais eficientes e pelo aumento do conhecimento acerca do assunto. Nesse sentido, o objetivo do presente estudo ? testar a hip?tese de que receptores do tipo 5-HT3 presentes na por??o dorsal do n?cleo dorsal da rafe (NDR) modulem as respostas relacionadas ? ansiedade em ratas. No experimento 1, ratas Wistar com ? 90 dias de idade receberam tratamento (v.o) de ondansetrona na dose de 0,1, 1 e 10 mg/kg/mL e, 60 minutos ap?s, foram submetidas ao teste do Labirinto em T Elevado (LTE). 24 horas ap?s o LTE, os animais receberam novamente a ondansetrona e foram submetidas ao teste do Campo Aberto. Nos experimentos 2 e 3, as ratas foram submetidas ? cirurgia estereot?xica para implanta??o de c?nula intra-NDR e receberam administra??o local de salina ou dolasetrona nas doses de 100, 500 e 1000nmol (experimento 2) ou salina ou mCPBG nas doses de 2,5, 5 e 10?g (experimento 3). Em ambos, 5 minutos ap?s a infus?o com a droga, os animais foram submetidos ao teste do LTE, e 24 horas ap?s, receberam infus?o e foram submetidos ao teste do Campo Aberto para obten??o de curvas doseresposta. A ondansetrona na dose de 10mg/Kg/mL aumentou a lat?ncia de fuga no LTE, sugerindo um efeito do tipo panicol?tico. A dolasetrona n?o promoveu nenhum efeito no teste do LTE, em nenhuma das doses testadas. J? o agonista mCPBG em todas as doses aumentou a lat?ncia de esquiva inibit?ria em todas as tentativas, sugerindo um efeito do tipo ansiog?nico. Os resultados obtidos no teste do Campo Aberto mostrou que n?o houve altera??o na atividade locomotora das ratas causada pelos tratamentos. Os dados obtidos refor?am a import?ncia dos receptores 5-HT3 no NDR na modula??o da ansiedade. / The involvement of both 5-HT3 receptors and dorsal raphe nucleus in the modulation of anxiety has been presented in the literature. Considering that most of population is affected by anxiety disorders, it is essential to search for new and more efficient forms of treatment and to increase the knowledge on the subject. The aim of this study is to test the hypothesis that the 5-HT3 receptors in the dorsal part of the dorsal raphe nucleus (dNDR) modulates the responses related to anxiety in rats. In experiment one, female Wistar rats with ? 90 days old were treated (p.o.) with ondansetron at doses of 0.1, 1 and 10 mg/kg/mL and 60 minutes later, were submitted to the elevated T maze (ETM) test. 24 hours later, they received ondansetron and were submitted to the open Field Test. In the experiments 2 and 3, the rats were submitted to the stereotactic surgery for implantation of intra-NDR cannula and received administration (via infusion) of saline or dolasetron at doses of 100, 500 and 1000nmol (experiment 2) or saline or mCPBG at doses of 2.5, 5 and 10mg (experiment 3). In both experiments, 5 minutes after the infusion of the drug, the animals were submitted to the test of ETM, and 24 hours after, they received drug infusion and were submitted to the open field test, to obtain dose-response curves. Ondansetron at a dose of 10mg/kg/mL increased latency of escape response in ETM, suggesting an panicolytic-like effect. The dolasetron caused no effect in ETM test in any of the tested doses. The agonist mCPBG instead, increased the inhibitory avoidance latency in all doses, suggesting an anxiogenic-like effect. Data obtained in the open field test showed no change in locomotor activity of rats following the treatments. The data here obtained supports the importance of 5-HT3 receptors in the NDR in the modulation of anxiety.

Serotonin receptors play a variety of functional roles in the body. Some indications and treatment claims for one of the classes of serotonin receptors, the 5-HT3 receptor family, include: anxiety, depression, chemotherapy- and radiation-induced emesis, constipation, irritable bowel syndrome, pain, drug addiction, and satiety control. A 5-HT3 receptor partial agonist, MD-354, served as a lead compound in the development of new 5-HT3 receptor ligands. Using halogenated analogs the study investigated their effect on binding to the 5-HT3 receptor. Conformationally-constrained analogs (quinazolines) were shown to be a novel class of 5-HT3 receptor antagonists. The log P values were determined for several analogs, and indicated that these ligands should be able to penetrate the blood-brain barrier. A homology model of the 5-HT3 receptor was built and the docking modes were assessed for these two series. Quinazolines were investigated for antidepressant properties using the mouse tail suspension test, and were shown to possess antidepressant-like activity.

The Dukat laboratory developed 2-amino-6-chloro-3,4-dihydroquinazoline (A6CDQ) as a 5-HT3 receptor ligand. A6CDQ and one of its positional isomers, the 7-chloro analog A7CDQ, produced antidepressant-like effects in the mouse tail suspension test (TST). We investigated and systematically ruled out a solely 5-HT3 receptor or hSERT mediated mechanism of antidepressant-like effect for both A6CDQ and A7CDQ. The role of organic cation transporter 3 (OCT3) as an alternative mechanism in the regulation of neurotransmitters including serotonin (5-HT) and the therapeutic potential of targeting hOCT3 to achieve antidepressant effects has been established. By virtue of possessing protonatable nitrogen atoms, 2-aminodihyroquinazolines could potentially exhibit activity at OCT3. A major goal of our present study was to explore the non-serotonergic mechanism of antidepressant-like effects and to study the as yet unexplored structure-activity-relationships (SARs) at OCT3. We examined the role of i) the chloro group, ii) the methylene bridge and iii) electronic/lipophilic effects at the 6-position. We developed the first 3-D homology models of both the human and mouse orthologs of OCT3, conducted docking studies and HINT analysis, and identified critical amino acid residues interacting with 2-aminodihydroquinazoline analogs at hOCT3 and mOCT3. Retention of antidepressant-like activity in the mouse and potential locomotor stimulant effects for TST-active doses were thoroughly investigated. We have successfully investigated initial SAR of 2-aminodihydroquinazolines at hOCT3 and generated the first 3-D homology models of hOCT3 and mOCT3. Highly potent and selective compounds could potentially be developed as radioligands to probe the binding site of OCT3 and as a mechanistically novel class of antidepressants.